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Objective. Ameloblastic carcinoma often poses diagnostic challenges in its separation from benign ameloblastoma with
atypical cytologic features or an unusual clinical course. This study aimed to determine whether SOX2 (sex determining
region-Y-related high mobility group box 2), a protein expressed in the epithelial basal proliferative zone in dentigerous cysts,
is a marker for ameloblastic carcinoma as well as for high-grade transformation in ameloblastic neoplasms.
Study Design. Immunoperoxidase stains were performed according to a standard protocol. Immunostains were interpreted
independently by 3 pathologists, and scores were recorded based on the percentage of staining and intensity of staining in the
cells of interest.
Results. The diffuse strong nuclear staining pattern has 86.4% specificity (19 of 22) to indicate the presence of high-grade
features and has 76.9% sensitivity (10 of 13) in comparison with benign counterparts (P ¼ .0021). Although previously shown
as a marker for ameloblastic neoplasms, calretinin is weakly positive in a few cells in 50% (5 of 10) of ameloblastic carcinoma
and 43% (3 of 7) of benign ameloblastic neoplasms, with little value in highlighting the high-grade change (P ¼ .36).
Conclusions. The diffuse nuclear staining pattern of SOX2 is suggestive of a high-grade process in ameloblastic neoplasms.
Numerous aggregates of cells harboring dense nuclear stain should raise concern for a malignancy. (Oral Surg Oral Med Oral
Pathol Oral Radiol 2014;117:608-616)Ameloblastic neoplasms represent a spectrum of en-
tities that arise from odontogenic epithelium. Based on
the histologic features, including ameloblastic differ-
entiation, mitotic rate, nuclear/cellular pleomorphism,
and the presence or absence of angiolymphatic/peri-
neural invasion, ameloblastic neoplasms are generally
categorized into ameloblastoma (AB), ameloblastic
carcinoma (AC), and an intermediate-grade atypical
ameloblastoma (AA).1
AC could develop de novo (primary type) or in an
existing ameloblastoma (secondary type, dediffer-
entiated) according to the recent World Health Orga-
nization classiﬁcation of these tumors.2 AC has a poor
prognosis with frequent metastases. In a recent review
of 31 AC cases, more than 75% were classiﬁed as the
secondary type, suggesting high-grade transformation
as a common mechanism underlying AC development.3
In fact, more than 60% of patients with AC had aaDepartment of Diagnostic Sciences, University of Pittsburgh School
of Dental Medicine.
bObafemi Awolowo University.
cDivision of Oral and Maxillofacial Surgery, Medical University of
South Carolina.
dDivision of Oral Pathology, Department of Stomatology, Medical
University of South Carolina.
eDepartment of Pathology & Laboratory Medicine, Emory University
School of Medicine.
Received for publication Oct 24, 2013; returned for revision Jan 5,
2014; accepted for publication Jan 9, 2014.
 2014 Elsevier Inc.
2212-4403
http://dx.doi.org/10.1016/j.oooo.2014.01.017
608
Open access under CC BY-NC-ND license.history of recurrence.3 Owing to the intermediate-grade
cytologic features and the limited extent of atypia seen
in an atypical ameloblastic lesion, the identiﬁcation of
areas undergoing high-grade transformation can be
challenging. Thus, a marker that would highlight these
worrisome areas in a preexisting ameloblastic lesion
and in a deﬁnitive AC would be of substantial assis-
tance in facilitating the diagnosis.
The histologic features of ameloblastic carcinoma or
an area of high-grade transformation in a preexisting
AB vary drastically. Although frank malignancy rarely
causes confusion in diagnosis, challenges arise in 2
scenarios: (1) in cases where the majority of the tumor
is bland without cytologic atypia, but focal areas show
loss of ameloblastic differentiation and presence of
high-grade features, such as nuclear/cytoplasmic pleo-
morphism, nuclear hyperchromasia, and increased
mitotic count1; and (2) in neoplasms that show inter-
mediate-grade features, that is, those seen in AA, in theStatement of Clinical Relevance
SOX2 immunohistochemical staining could reliably
separate ameloblastic carcinomas from benign ame-
loblastic lesions. We recommend including this
stain, in conjunction with Ki-67, to facilitate
the diagnosis of a challenging case with atypical
features.
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Some pilot studies focused on the selection of sensitive
immunohistochemical (IHC) markers for the differen-
tial diagnosis. A number of IHC markers are suggested
to be helpful in facilitating the diagnosis, such as the
proliferation index Ki-67 labeling and smooth muscle
actin (SMA).3,4 However, the reported Ki-67 index
varies between 2% and 80% in AC,3 and the sensitivity
of SMA remains to be further substantiated.
In this study, we aimed to discover a novel marker
that is sensitive to highlight the high-grade trans-
formation areas of AB and reliably stain AC. To select
such a marker, we used an algorithm that took into
account 3 aspects of AC development: (1) evidence of
involvement in ameloblast development; (2) the ability
to promote high-grade transformation; and (3) a proven
role in carcinogenesis. Using immunohistochemistry,
we screened a panel of proteins, including calretinin,
CD56, CD138, b-catenin, SMA, and SOX2 (sex
determining region-Y-related high mobility group box
2). All these proteins have been reported to stain
ameloblastic neoplasms or to be involved in amelo-
blastic epithelium lineage development,4-11 and only
SOX2 simultaneously fulﬁlled all 3 of the aforemen-
tioned criteria. Fluorescence in situ hybridization
(FISH) was used to assess SOX2 gene ampliﬁcation.
The SOX2 protein contains a high-mobility-group
domain, with above 50% homology to that of the
mammalian testis-determining factor Sry. SOX2 is well
established as a pivotal transcription factor that modu-
lates embryonic stem cell (ESC) self-renewal and dif-
ferentiation.12 A seminal study identiﬁes SOX2 as 1 of
the 4 essential transcription factors that could be har-
nessed to reprogram differentiated ﬁbroblasts to
pluripotent stem cells.13 In the earliest ESC differenti-
ation stage, SOX2 promotes ectodermal development,
which gives rise to odontogenic epithelium.12 Indeed, 2
recent studies found that Sox2 is expressed in dental
lamina and is involved in the renewal of all epithelial
cell lineages of tooth development, including amelo-
blasts, in mouse models.11,14 SOX2 mRNA expression
in the epithelial stem cell niche of a developing tooth is
meticulously regulated in a temporal fashion, which
shows a gradually more conﬁned expression in a later
stage compared with a diffuse expression pattern in the
early stage of development.11
Given its potent role in modulating cell self-renewal
and proliferation, SOX2 is rapidly emerging as an
oncogene in many epithelial cancers.12 Pilot single-
nucleotide polymorphism array and comprehensive
genomic analyses on human lung squamous cell car-
cinoma, lung small cell carcinoma, and esophageal
squamous cell carcinoma show prominent SOX2
ampliﬁcation.15,16 SOX2 has been linked to a more
aggressive clinical course and poorer outcomes inovarian cancer,17 urothelial carcinoma,18 breast tu-
mors,19 esophageal carcinoma,20 nasopharyngeal car-
cinoma,21 and oral squamous cell carcinoma.22,23
In this study, by analyzing one of the largest re-
ported collections of human AC parafﬁn-embedded
tissue samples, we found that SOX2 is a speciﬁc and
sensitive marker for AC. Strong nuclear staining of
aggregates of tumor cells that are devoid of classic
ameloblastic differentiation suggests high-grade fea-
tures of the ameloblastic neoplasm, and raises caution
for a secondary-type AC arising in an otherwise well-
differentiated AB.MATERIALS AND METHODS
Ethics statement and study participants
This study was approved by the Institutional Review
Board of the University of Pittsburgh. We included
parafﬁn-embedded tissues from 16 cases of AB, 6 of
AA, and 13 of AC. Cases were retrieved from the
archives of the University of Pittsburgh (Pittsburgh,
PA, USA), Emory University (Atlanta, GA, USA),
the Medical University of South Carolina
(Charleston, SC, USA), and the Obafemi Awolowo
University (Ile-Ife, Nigeria). All patients’ records
were kept conﬁdential and made accessible only to
the research group.Interpretation of IHC stain scores
Immunoperoxidase stains were performed according to
a standard protocol on the BenchMark Ultra platform
(Ventana Medical Systems Inc). The antibodies
included anti-calretinin (18-0211; Invitrogen, Carlsbad,
CA, USA), anti-SOX2 (3579S; Cell Signaling, Dan-
vers, MA, USA), anti-CD56 (123C3.D5; Cell Marque,
Rocklin, CA, USA), anti-CD138 (MI15; Dako, Car-
pinteria, CA, USA), anti-b-catenin (b-Catenin-1;
Dako), and anti-SMA (1A4; Cell Marque). Immunos-
tains were interpreted independently by 3 pathologists
(Y.L., J.M.J, E.A.B.), and scores were recorded based
on the percentage of staining (1-4, representing
0%-25%, 26%-50%, 51%-75%, and 76%-100%,
respectively) and intensity of staining (0-3, representing
negative, minimal, intermediate, and strong staining,
respectively) in the cells of interest. An IHC score of
less than 6 was considered negative.SOX2 FISH analysis
Dual-color SOX2 FISH analysis was performed using a
Spectrum Green labeled CEP3 probe (Abbott Molecu-
lar, Des Plaines, IL, USA) and a Spectrum Orange
labeled probe, RP11-43F17 (CHORI, Oakland, CA,
USA). Nuclei were counterstained with DAPI/antifade
(Abbott Molecular, Des Plaines, IL, USA). Analyses
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(DM5500 B; Leica) and Cytovysion Workstation
(Applied Imaging, Santa Clara, CA, USA). The histo-
logic areas previously selected on the hematoxylin-eosin
stained sections were identiﬁed on the FISH-treated
slides. Only individual and well-delineated cells were
scored. Overlapping cells were excluded from the
analysis. At least 60 cells were assessed for each case.Statistical analysis
Comparisons of IHC scores among the 3 different
groups were made by a Kruskal-Wallis 1-way analysis
of variance, followed by the Dunn multiple comparison
test to compare IHC scores of any given pair of the 3
groups. Analyses were made using GraphPad Prism 5.0
(GraphPad Software Inc). A value of P < .05 was
considered to be signiﬁcant.RESULTS
Histologic diagnostic criteria for ameloblastic
lesions
We included 16 AB, 6 AA, and 13 AC cases in this
study. The diagnostic criteria of AC are (1) at least 2
mitotic ﬁgures per high-power ﬁeld in the high-grade
area; (2) the presence of focal ameloblastic epithelium
exhibiting palisading with reverse polarity; (3) the
presence of cytologic atypia such as cytoplasmic or
nuclear pleomorphism (or both); and (4) histologic
signs of malignancy, such as extensive necrosis or
angiolymphatic or perineural invasion. An aggressive
clinical course with distant metastasis will facilitate the
diagnosis. The histologic features of AA fall into
the intermediate category compared with AB and AC.
The criteria used to establish a diagnosis of AA in this
study included (1) focal loss of classic ameloblastic
differentiation; (2) increased crowding and cytologic
pleomorphism (but no area should show a mitotic count
of 2 or more per high-power ﬁeld); and (3) absence of
angiolymphatic or perineural invasion.Identification of SOX2 as a marker for AC
To discover a speciﬁc and sensitive marker that facili-
tates the separation of high-grade ameloblastic lesions
from a benign AB, we used the aforementioned criteria,
taking into account multiple aspects of AC develop-
ment, and screened a panel of markers that have been
reported to stain ameloblastic epithelium. This panel of
proteins included SOX2, calretinin, CD56, CD138,
b-catenin, and SMA.
In our study, we found that calretinin was variably
positive in 25.0% of the 4 tested AB cases, 66.7% of
the 3 AA cases, and 50.0% of the 10 AC cases. In
general, the staining was variable in density and markedonly a small portion of the lesional cells. The IHC
technical controls for calretinin were consistently pos-
itive. The density and percent of area of calretinin IHC
stain were comparable among the tested ameloblastic
neoplasms (P ¼ .36). In agreement with previous evi-
dence,7,8 we also observed frequent CD56 and CD138
staining in ameloblastic epithelium. However, the
staining patterns of CD56 and CD138 carried little
value in the differential diagnosis of benign and ma-
lignant ameloblastic lesions (P ¼ .42 and P ¼ .37,
respectively).
The nuclear translocation of b-catenin and subse-
quent activation of the Wnt signaling axis are important
mechanisms underlying the epithelial-mesenchymal
transition of carcinoma cells, promoting invasion.24 A
recent study found that b-catenin reactivity could be
seen in AB and AC.9,10 With the IHC scoring system
used in this study, 33.3% of the AB were positive for b-
catenin, but neither 2 tested AA nor 3 tested AC cases
showed positive b-catenin nuclear staining (P ¼ .21).
We also investigated the staining pattern of SMA,
and only cytoplasmic staining was considered positive.
In the 4 tested AB and 3 tested AA cases, SMA stains
were completely negative. One of the 2 stained AC
cases showed focal weak staining with an IHC score of
2, which was considered negative in this study. No
difference was found among all 3 groups (P ¼ .17)
(Figure 1; Figure 2, A).
In our pilot screening panel, only SOX2 IHC
demonstrated a signiﬁcant difference in density and the
percentage of the tumor stained. In agreement with its
biologic function as a transcription factor, SOX2 IHC is
a nuclear stain, and occasional weak cytoplasmic
staining was considered nonspeciﬁc. The SOX2 IHC
scores in 13 tested AC were signiﬁcantly higher than in
16 AB or 6 AA cases (P ¼ .0021) (see Figure 1; see
Figure 2, A). The IHC score of AC was signiﬁcantly
higher than that of AB or AA; however, no difference
was present between the IHC scores of the AB and AA
groups. Overall, SOX2 staining was essentially nega-
tive in most AB or AA, with occasional positivity in
tumor cells. We included follicular, plexiform, granular
cell, and acanthomatous types of AB in the study
(Supplemental Table S1; available at http://dx.doi.org/
10.1016/j.oooo.2014.01.017). The SOX2 staining was
negative in 14 of 16 AB cases (87.5%) with a score of
less than 6, regardless of the subtypes. Although the 2
acanthomatous type AB specimens appeared to have a
higher IHC score, the number of cases for this particular
type may limit the interpretation. In contrast, SOX2 was
diffusely and strongly positive in the tumor islands in
AC. To determine if SOX2 gene ampliﬁcation was more
prominent in AC compared with the benign counter-
parts, we used FISH to investigate the hyperploidy of
SOX2. An average of 8.7% of the examined cells in AB
Fig. 1. Identiﬁcation of SOX2 as a sensitive marker for ameloblastic carcinoma. Ameloblastoma, atypical ameloblastoma, or
ameloblastic carcinoma parafﬁn-embedded tissue were processed and analyzed with hematoxylin-eosin stain and immunohisto-
chemical stains for SOX2, calretinin, CD56, CD138, b-catenin, and SMA (original magniﬁcation 400; representative areas are
shown). (SMA, smooth muscle actin; SOX2, (sex determining region-Y-related high mobility group box 2).)
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ploidy (see Figure 2, B).
SOX2 highlighted areas suspicious for high-grade
transformation
AC with exuberant proliferation of dedifferentiated tu-
mor cells, substantially increased mitotic count, andangiolymphatic or perineural invasion usually does not
lead to a diagnostic dilemma. However, challenges
arise in ameloblastic neoplasms with only focal areas of
suspicion for high-grade transformation or intermediate
cytologic atypia.
As one example of such a conundrum, the following
difﬁcult case, with a retrospective review of the history,
Fig. 2. IHC proﬁles and SOX2 ampliﬁcation. A, The IHC scores were calculated based on the area and density of each stain.
Results were graphed using the mean  standard error of the mean. Comparison among groups is made by Kruskal-Wallis 1-way
analysis of variance. B, Fluorescence in situ hybridization analysis of SOX2 gene ampliﬁcation. At least 60 individual cells were
counted, and the percentage of hyperploidy was shown. (IHC, immunohistochemical; SOX2, (sex determining region-Y-related
high mobility group box 2); SMA, smooth muscle actin.)
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the diagnosis. A 63-year-old man presented with an
ameloblastic neoplasm with > 90% of the lesional cells
demonstrating classic ameloblastic differentiation.
However, the tumor also harbored focal aggregates of
tumor cells that lacked ameloblastic differentiation and
exhibited moderate cytoplasmic or nuclear pleomor-
phism (Figure 3, upper panels). To better appreciate the
distinction of these small focal aggregates, we per-
formed SOX2 IHC stain and found that the atypical
cells demonstrated diffuse and strong nuclear staining,
whereas the area of classic ameloblastoma was
completely negative (Figure 3, lower panels). The pa-
tient developed multiple recurrences with epidural
involvement. After 2 skull base surgeries for the tumor,
the patient died 3 years after initial presentation.
Some ameloblastic lesions may present with worri-
some clinical and radiographic features, but the histo-
logic examination shows intermediate-grade cytologic
atypia or very focal areas of dedifferentiation. One such
example occurred in a 46-year-old white man, who
presented with a recurrent ameloblastic lesion. The
patient had a history of an ameloblastoma in the right
mandible 9 years previously, and there was extensive
recurrence of the tumor, which expanded into the
overlying soft tissue (Figure 4, A). Radiographic ex-
amination showed a large multilocular radiolucent
lesion involving the right body of the mandible.
Destruction of the cortical bone of the inferior border
of the mandible and resorption of the roots of multiple
teeth were also present (see Figure 4, B). However,
cytologic atypia was only noted in focal areas. Nuclear
hyperchromasia, pleomorphism, cellular crowding,
and cytologic atypia were present in focal areas,
whereas the rest of the tumor cells maintained classicameloblastic differentiation (see Figure 4, C). SOX2
staining highlighted only the atypical cells, but the
classic ameloblastic epithelium was negative (see
Figure 4, D). The overall staining of SOX2 was less
than 5% of the tumor cells. In conjunction with the
histologic features, this case was diagnosed as AA, and
SOX2 was useful in highlighting the cytologic atypia
that was subtle despite the aggressive clinical and
radiographic presentation.Staining pattern of SOX2 in dentigerous cyst
Consistent with previous ﬁndings that SOX2 promotes
epithelial cell renewal and proliferation, we also found
SOX2 was strongly positive in the basal layer of den-
tigerous cyst epithelium (Figure 5) and surface mucosal
epithelium. In this context, SOX2 staining is not
indicative of high-grade transformation as in amelo-
blastic neoplasms.DISCUSSION
SOX2 is a speciﬁc and sensitive marker for high-grade
ameloblastic neoplasms. Diagnostic dilemma in ame-
loblastic lesions often arises in 2 scenarios: (1) the
cytologic atypia and loss of ameloblastic differentiation
are intermediate, and cannot be easily categorized into
either AA or AC; or (2) depending on the relative extent
of the cytologic atypia and high-grade transformation,
confusing overlapping histologic features exist between
AA and AC.1 Some IHC stains have been reported as
valuable ancillary studies for AC. For example, the
proliferation marker Ki-67 index is signiﬁcantly higher
in AC than in AB. However, the interpretation of Ki-67
index increase is somewhat subjective, and Ki-67 index
varies between 2% and 80% in AC.3 A previous study
Fig. 3. SOX2 highlights areas suspicious for high-grade transformation. Upper panels show representative sections of conventional
ameloblastoma and areas with high-grade features. The lower panels show SOX2 immunohistochemical stain of conventional
ameloblastoma and areas with high-grade features on the same histologic section (original magniﬁcation 400). (SOX2, SRY [sex
determining region Y]-box 2.)
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for AC.4 In our study, we found that the intensity and
percentage of staining for SMA do not differ signiﬁ-
cantly between benign ameloblastic lesions and AC.
Calretinin is another protein that has been reported to
stain the stellate reticulum of AB, but not the columnar
ameloblasts at the periphery.5,6 According to our single-
institution experiences, both in clinical service and in
this study, we have found this cytoplasmic stain to be
highly variable and sometimes too weak to interpret. In
addition, in a recent microgenomic study of AB,
mRNA of CALB2 (Calbindin 2), which encodes calre-
tinin, was elevated in the columnar ameloblasts.25 The
cause of this discrepancy in the use of calretinin IHC is
unclear, but the collective evidence suggests that the
staining of calretinin in AB may be technically sensitive
and depend on the clones of antibodies. In a subset of
AA and AC, we found variable staining of calretinin,
but there was no statistical signiﬁcance between the
IHC scores. In contrast, we found that SOX2 is a highly
speciﬁc (86.4%) and sensitive (76.9%) marker for AC.
As a transcription factor, SOX2-positive cells in AC
usually form aggregates that recapitulate the tumor
islands with high-grade features. Thus the combination
of SOX2 and Ki-67 is recommended to facilitate the
diagnosis of a challenging case.
SOX2 is indispensable for the homeostasis of stratiﬁed
squamous epithelium. In several studies with mouse
models, Sox2 was found to mediate the development ofesophagus.26 In adult mice, Sox2 showed prominent
protein expression in the basal layer of esophageal
stratiﬁed squamous mucosa.27 In our study, we observed
a similar pattern, with SOX2 expression usually being
restricted to the cells in the proliferation zone of stratiﬁed
squamous mucosa of the oral cavity or of a dentigerous
cyst. This expression pattern is consistent with its role in
maintaining the physiologic turnover of the squamous
mucosa. Thus, the SOX2 stain should be interpreted with
caution in the context of connections with surface
epithelium or a dentigerous cyst. It is of importance to
appreciate this interpretation caveat and recognize that
carryover of surface epithelial staining for SOX2 does
not warrant a diagnosis of high-grade transformation or
AC. In fact, when SOX2 IHC is combined with histo-
logic characterization and clinical history, the rendering
of a benign peripheral AB diagnosis is not likely to cause
any confusion.
SOX2 staining could serve as a useful marker to
highlight areas undergoing high-grade transformation
in an atypical ameloblastoma. We appreciate that the
size of our cohort and the testing of markers other than
SOX2 in a few cases may limit the interpretation of the
results, and experiences from multiple institutions
would be very beneﬁcial to further evaluate the utility
of SOX2 as a potential marker for AC and in the sep-
aration of AC from AA. In the 6 included AA cases, we
consistently found that the SOX2 expression pattern
was substantially different from that of AC. In AA, the
Fig. 4. SOX2 staining in an atypical ameloblastoma. A 46-year-old white man presented with an atypical ameloblastoma with
aggressive clinical (A) and radiographic (B) features. C, Hematoxylin-eosin, original magniﬁcation 400. D, SOX2 immuno-
histochemical staining, original magniﬁcation 400. (SOX2, sex determining region-Y-related high mobility group box 2.)
Fig. 5. SOX2 staining pattern in a dentigerous cyst. Both he-
matoxylin-eosin and SOX2 immunohistochemical stains are
shown in the same area of a dentigerous cyst. SOX2 highlights
the proliferative cells of the stratiﬁed squamous epithelium.
(Representative pictures, original magniﬁcation400). (SOX2,
sex determining region-Y-related high mobility group box 2.)
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ameloblastoma-like morphology were negative for SOX2.
In focal areas that showed some degree of cytologic atypia,
increased cellularity, and loss of ameloblastic differentia-
tion, SOX2 was strongly positive in aggregates of tumor
cells.
The biologic functions of SOX2 may be expression
level dependent. Although a normal level of murine
Sox2 expression is observed in the basal layer of
stratiﬁed squamous mucosa, an exogenous expression
of high-level Sox2 in these cells substantially promotes
the development of squamous cell carcinoma.27 In a
recent report, a group found that 5 AB cases were
positive for SOX2.28 However, no score of the overall
staining pattern was reported, and no AA or AC was
included for comparison. In contrast to their results,
87.5% of our tested AB cases were negative for SOX2.Two different clones of antibodies were used in the
studies, which may partially explain the discrepancy.
The different titrations of the antibodies would also lead
to a substantial difference in IHC staining. Hence, it is
essential to compare SOX2 staining in a spectrum of
ameloblastic lesions, from ameloblastoma to amelo-
blastic carcinoma, and to establish a standard staining
protocol. With an optimized protocol at our institution,
all IHC staining in this study was performed on the
same Ventana BenchMark Ultra automated IHC/ISH
slide staining system. We consistently found strong
nuclear positivity of SOX2 in AC, in comparison with
only scattered positivity in the benign counterparts.
The protein level of SOX2 is more indicative of the
development of AC than the SOX2 gene hyperploidy.
We found that SOX2 gene hyperploidy was not elevated
in AC, which is not concordant with the higher protein
expression level revealed by our IHC study. With the
emerging landscape of the posttranslational regulatory
mechanisms of this critical transcription factor, the
upregulation of SOX2 in AC may be a result of
increased protein stability. In fact, it has been found that
acetylation and sumoylation of Sox2 control its protein
stability, and that phosphorylation is involved in protein
transcriptional activation.12
SOX2 promotes epithelial high-grade transformation
through an orchestrated set of mechanisms. SOX2 is a
pivotal factor maintaining the self-renewal of cancer
initiating cells of both breast cancer and glioblas-
toma.29,30 Overexpression of Sox2, in conjunction with
another microenvironment-activated transcription factor
Stat3, promotes the malignant transformation of murine
OOOO ORIGINAL ARTICLE
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matory signaling to convert epithelial progenitor cells to
invasive squamous carcinoma cells.27 Epidermal
growth factor receptor (EGFR) overexpression is pre-
sent in over 80% of head and neck squamous cell
carcinoma (HNSCC) cases. Targeted EGFR adjuvant
therapy is a proven effective strategy in a subset of
patients with HNSCC.31 SOX2 increases the expression
of EGFR mRNA, and activated EGFR signaling further
induces SOX2 expression, forming a positive feedback
loop.32 The crosstalk between SOX2 and EGFR
signaling in odontogenic carcinomas remains to be
further investigated.
CONCLUSION
By comparing a panel of molecules, we identiﬁed a
highly sensitive and speciﬁc marker, SOX2, to highlight
high-grade ameloblastic neoplasms. SOX2 IHC is
negative or shows only scattered positive cells in AB or
AA, but it is diffusely positive in AC tumor aggregates.
The SOX2 gene hyperploidy is not concordant with IHC
results and has little value in separating AC from its
benign counterparts. Owing to the role of SOX2 in
maintaining squamous mucosa homeostasis, it is usually
positive in the basal proliferation zone. Thus amelo-
blastic lesions with extensive connections to the surface
epithelium or the epithelial lining of a dentigerous cyst
may show strong nuclear SOX2 positivity, which should
be interpreted with caution. We recommend SOX2 IHC
stain, in conjunction with Ki-67, be included in the
staining panel for ameloblastic neoplasms.
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Supplemental Table S1. SOX2 immunohistochemical
staining pattern and histologic variants of ameloblastoma
Case Histologic subtype
Percentage
of staining
Intensity
of staining
Overall
score
1 Follicular type 1 0 0
2 Follicular type 1 0 0
3 Follicular type 1 0 0
4 Follicular type 1 3 3
5 Follicular type 1 3 3
6 Follicular type 1 2 2
7 Plexiform type 1 0 0
8 Plexiform type 2 2 4
9 Plexiform type 1 1 1
10 Plexiform type 1 2 2
11 Granular cell with follicular
type
1 0 0
12 Granular cell with follicular
type
1 3 3
13 Granular cell type 2 3 6
14 Acanthomatous type; cannot
entirely rule out being
peripheral
2 2 4
15 Acanthomatous type 3 2 6
16 Peripheral (no surface
connection noted in the
stained sections)
1 1 1
The histologic subtypes, percentage of staining area, intensity of
staining, and overall immunohistochemical score are shown for all of
the 16 ameloblastoma cases we included in this study.
SOX2, sex determining region-Y-related high mobility group box 2.
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